Show simple item record

dc.contributor.authorSpadaro, Alessandro
dc.contributor.authorNegri, Matthias
dc.contributor.authorMarchais-Oberwinkler, Sandrine
dc.contributor.authorBey, Emmanuel
dc.contributor.authorFrotscher, Martin
dc.date.accessioned2012-10-18T11:35:47Z
dc.date.available2012-10-18T11:35:47Z
dc.date.issued2012
dc.identifier.citationHydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1). 2012, 7 (1):e29252 PLoS ONEen_GB
dc.identifier.issn1932-6203
dc.identifier.pmid22242164
dc.identifier.doi10.1371/journal.pone.0029252
dc.identifier.urihttp://hdl.handle.net/10033/249356
dc.description.abstract17β-estradiol (E2), the most potent estrogen in humans, known to be involved in the development and progession of estrogen-dependent diseases (EDD) like breast cancer and endometriosis. 17β-HSD1, which catalyses the reduction of the weak estrogen estrone (E1) to E2, is often overexpressed in breast cancer and endometriotic tissues. An inhibition of 17β-HSD1 could selectively reduce the local E2-level thus allowing for a novel, targeted approach in the treatment of EDD. Continuing our search for new nonsteroidal 17β-HSD1 inhibitors, a novel pharmacophore model was derived from crystallographic data and used for the virtual screening of a small library of compounds. Subsequent experimental verification of the virtual hits led to the identification of the moderately active compound 5. Rigidification and further structure modifications resulted in the discovery of a novel class of 17β-HSD1 inhibitors bearing a benzothiazole-scaffold linked to a phenyl ring via keto- or amide-bridge. Their putative binding modes were investigated by correlating their biological data with features of the pharmacophore model. The most active keto-derivative 6 shows IC₅₀-values in the nanomolar range for the transformation of E1 to E2 by 17β-HSD1, reasonable selectivity against 17β-HSD2 but pronounced affinity to the estrogen receptors (ERs). On the other hand, the best amide-derivative 21 shows only medium 17β-HSD1 inhibitory activity at the target enzyme as well as fair selectivity against 17β-HSD2 and ERs. The compounds 6 and 21 can be regarded as first benzothiazole-type 17β-HSD1 inhibitors for the development of potential therapeutics.
dc.language.isoenen
dc.rightsArchived with thanks to PloS oneen_GB
dc.subject.mesh17-Hydroxysteroid Dehydrogenasesen_GB
dc.subject.meshCell Line, Tumoren_GB
dc.subject.meshCrystallizationen_GB
dc.subject.meshEnzyme Inhibitorsen_GB
dc.subject.meshEstrogen Receptor alphaen_GB
dc.subject.meshEstrogen Receptor betaen_GB
dc.subject.meshEstrogens, Non-Steroidalen_GB
dc.subject.meshHumansen_GB
dc.subject.meshLigandsen_GB
dc.subject.meshModels, Molecularen_GB
dc.subject.meshStructure-Activity Relationshipen_GB
dc.subject.meshThiazolesen_GB
dc.titleHydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1).en
dc.typeArticleen
dc.contributor.departmentPharmaceutical and Medicinal Chemistry, Saarland University, Saarbrücken, Germany.en_GB
dc.identifier.journalPloS oneen_GB
refterms.dateFOA2018-06-13T19:35:16Z
html.description.abstract17β-estradiol (E2), the most potent estrogen in humans, known to be involved in the development and progession of estrogen-dependent diseases (EDD) like breast cancer and endometriosis. 17β-HSD1, which catalyses the reduction of the weak estrogen estrone (E1) to E2, is often overexpressed in breast cancer and endometriotic tissues. An inhibition of 17β-HSD1 could selectively reduce the local E2-level thus allowing for a novel, targeted approach in the treatment of EDD. Continuing our search for new nonsteroidal 17β-HSD1 inhibitors, a novel pharmacophore model was derived from crystallographic data and used for the virtual screening of a small library of compounds. Subsequent experimental verification of the virtual hits led to the identification of the moderately active compound 5. Rigidification and further structure modifications resulted in the discovery of a novel class of 17β-HSD1 inhibitors bearing a benzothiazole-scaffold linked to a phenyl ring via keto- or amide-bridge. Their putative binding modes were investigated by correlating their biological data with features of the pharmacophore model. The most active keto-derivative 6 shows IC₅₀-values in the nanomolar range for the transformation of E1 to E2 by 17β-HSD1, reasonable selectivity against 17β-HSD2 but pronounced affinity to the estrogen receptors (ERs). On the other hand, the best amide-derivative 21 shows only medium 17β-HSD1 inhibitory activity at the target enzyme as well as fair selectivity against 17β-HSD2 and ERs. The compounds 6 and 21 can be regarded as first benzothiazole-type 17β-HSD1 inhibitors for the development of potential therapeutics.


Files in this item

Thumbnail
Name:
spadaro et al_final.pdf
Size:
996.5Kb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record